Evidence map›Paper›PMID 35803526›Full record

ArticleTransplantation and cellular therapy2022

Effect of Cryopreservation in Unrelated Bone Marrow and Peripheral Blood Stem Cell Transplantation in the Era of the COVID-19 Pandemic: An Update from the Japan Marrow Donor Program.

Yoshinobu Kanda, Noriko Doki, Minoru Kojima, Shinichi Kako, Masami Inoue, Naoyuki Uchida, Yasushi Onishi, Reiko Kamata, Mika Kotaki, Ryoji Kobayashi and 10 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation and cellular therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 16 institutions in 1 country.

Yoshinobu KandaDivision of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan. Electronic address: ycanda-tky@umin.ac.jp.
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Minoru KojimaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Shinichi KakoDivision of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
Masami InoueDepartment of Hematology/Oncology, Osaka Women's and Children's Hospital, Osaka, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
Naoyuki UchidaDepartment of Hematology, Toranomon Hospital, Tokyo, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
Yasushi OnishiDepartment of Hematology, Tohoku University Hospital, Sendai, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
Reiko KamataNonprofit Organization Blood Disorder Information and Support Service "Tsubasa", Tokyo, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
Mika KotakiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
Ryoji KobayashiDepartment of Hematology/Oncology for Children and Adolescents, Sapporo Hokuyu Hospital, Sapporo, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
Junji TanakaDepartment of Hematology, Tokyo Women's Medical University, Tokyo, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
Nobuharu FujiiDivision of Blood Transfusion, Okayama University Hospital, Okayama, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
Koichi MiyamuraDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
Shin-Ichiro MoriHematology Department, St. Luke's International Hospital, Tokyo, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
Yasuo MoriMedicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
Yasuo MorishimaDepartment of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
Hiromasa YabeDepartment of Innovative Medical Science, Tokai University School of Medicine, Isehara, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Aichi, Japan; Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan.
Yoshihisa KoderaAichi Medical University School of Medicine, Aichi, Japan.
Aichi Medical University · JPJichi Medical University · JPTokyo Metropolitan Komagome Hospital · JPJapanese Red Cross Nagoya Daiichi Hospital · JPKyushu University · JPOkayama University Hospital · JPOsaka Women's and Children's Hospital · JPResearch Organization of Information and Systems · JPSapporo Hokuyu Hospital · JPSt. Luke's International Hospital · JPThe Japanese Data Center for Hematopoietic Cell Transplantation · JPTohoku University Hospital · JPTokai University · JPTokyo National Hospital · JPTokyo Women's Medical University · JPToranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the COVID-19 pandemic, donor grafts are frequently cryopreserved to ensure that a graft is available before starting a conditioning regimen. However, there have been conflicting reports on the effect of cryopreservation on transplantation outcomes. Also, the impact of cryopreservation may differ in bone marrow (BM) transplantation (BMT) and peripheral blood stem cell (PBSC) transplantation (PBSCT). In this retrospective study, we analyzed the clinical data of both cryopreserved unrelated BMTs (n = 235) and PBSCTs (n = 118) and compared these with data from a large control cohort without cryopreservation including 4133 BMTs and 720 PBSCTs. Among the patients with cryopreserved grafts, 10 BMT recipients (4.3%) and 3 PBSCT recipients (2.5%) did not achieve neutrophil engraftment after transplantation, including 4 of the former and all 3 of the latter who died early before engraftment. In a multivariate analysis, cryopreservation was not associated with neutrophil engraftment in BMT but significantly delayed neutrophil engraftment in PBSCT (hazard ratio [HR], .82; 95% confidence interval [CI], .69 to .97; P = .023). There was an interaction with borderline significance between cryopreservation and the stem cell source (P = .067). Platelet engraftment was delayed by cryopreservation after both BMT and PBSCT. Only 2 cryopreserved grafts (<1%) were unused during the study period. The cryopreservation of unrelated donor BM and PBSC grafts is associated with a slight delay in neutrophil and platelet engraftment but an acceptable rate of graft failure. PBSC grafts may be more sensitive to cryopreservation than BM grafts. Cryopreservation is a reasonable option during COVID-19 pandemic, provided that the apheresis and transplantation centers are adept at cryopreservation. © 2022 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

Indexed as

COVID-19Graft vs Host DiseasePeripheral Blood Stem Cell TransplantationBone MarrowHumansJapanPandemicsRetrospective StudiesUnited StatesBone marrow transplantationCOVID-19CryopreservationJapan Marrow Donor ProgramPeripheral blood stem cell transplantation

Identifiers

PMID35803526
PMCPMC9259068
OpenAlexW4284990074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.